Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 86
Filtrar
1.
Clin Ther ; 20(5): 978-89, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9829449

RESUMEN

The objective of this study was to determine the incidence of dry cough in hypertensive patients with a history of angiotensin-converting enzyme (ACE) inhibitor-induced cough after treatment with losartan (an angiotensin II-receptor antagonist), lisinopril (an ACE inhibitor), or placebo. One hundred patients from 16 outpatient treatment centers in the United States were included in this double-masked, randomized, parallel-group, active- and placebo-controlled study, with stratification according to sex. After a challenge phase with lisinopril and a placebo washout phase, patients were randomly allocated to receive losartan 50 mg once daily, lisinopril 20 mg once daily, or placebo for a maximum of 8 weeks. The primary efficacy end point of the study was the presence or absence of dry cough during the double-masked period, as rated by the patient at each visit using a validated symptom assessment questionnaire. A secondary end point was the frequency of dry cough, as measured at each visit using a visual analogue scale (VAS). The incidence of dry cough was significantly higher in the lisinopril group than in the losartan and placebo groups (87.5% vs 36.7% and 31.4%, respectively) at the end of the double-masked treatment period; there was no statistically significant difference between the losartan and placebo groups. Mean VAS scores showed that patients treated with lisinopril rated themselves as having a significantly higher frequency of cough than did patients treated with losartan or placebo (4.0 vs 1.2 and 1.5, respectively). Again, the difference between the losartan and placebo groups was not statistically significant. All treatments were otherwise well tolerated, and no serious clinical or laboratory adverse events were reported during the double-masked phase of the study. These results demonstrate that the incidence, severity, and frequency of dry cough in patients with a history of ACE inhibitor-induced dry cough are significantly lower in those treated with losartan than in those treated with lisinopril and are similar to the incidence, severity, and frequency of dry cough in those receiving placebo.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Antihipertensivos/efectos adversos , Tos/inducido químicamente , Hipertensión/tratamiento farmacológico , Losartán/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad
2.
Hypertension ; 31(4): 925-8, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9535416

RESUMEN

Unexplained, persistent cough limits the use of angiotensin-converting enzyme (ACE) inhibitors in a significant number of patients. It has been speculated that occurrence of this adverse effect is genetically predetermined; in particular, variants of the genes encoding ACE, chymase, and B2-bradykinin receptor have been implicated. To investigate this question, we determined genotypes for common polymorphisms for these three genes in subjects with a history of ACE inhibitor-related cough. Specificity of the adverse effect was confirmed by a blinded, double-crossover design protocol in which subjects were rechallenged with either lisinopril or placebo. In 99 case subjects and 70 control subjects (who failed to develop cough on rechallenge with ACE inhibitor) thus selected, frequencies for the ACE D and I alleles were 0.56 and 0.44 (cases) and 0.56 and 0.44 (controls), respectively; frequencies for chymase A and B alleles (absence/presence of BstXI site) were 0.56 and 0.44 (cases) and 0.46 and 0.54 (controls), respectively; frequencies for B2-bradykinin receptor + and - alleles (presence/absence of a 21 to 29 nonanucleotide sequence) were 0.52 and 0.48 (cases) and 0.53 and 0.47 (controls), respectively. All observed genotype frequencies were in Hardy-Weinberg equilibrium. There was no evidence for association between genotype at either gene examined and cough (adjusted for gender and age). Our data indicate that common genetic variants of ACE, chymase, and B2-bradykinin receptor do not explain the occurrence of ACE inhibitor-related cough.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Tos/inducido químicamente , Tos/genética , Frecuencia de los Genes/genética , Peptidil-Dipeptidasa A/genética , Receptores de Bradiquinina/genética , Serina Endopeptidasas/genética , Quimasas , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Polimorfismo Genético
3.
Blood Press ; 6(1): 35-43, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9116924

RESUMEN

The antihypertensive activity of losartan potassium (losartan, Cozaar), an angiotensin II receptor antagonist, was evaluated in a parallel 12-week, double-blind, placebo-controlled trial in hypertensive patients with mild-to-moderate hypertension. After a 4-week, single-blind, placebo lead-in period, which included monitoring of baseline variables, 366 patients with a group mean sitting diastolic blood pressure of 101 +/- 5 (s.d.) mmHg were assigned randomly to one of three treatment groups: placebo, losartan 50 mg, or losartan 50 mg with the option to titrate to 100 mg after the first 6 weeks if the target sitting diastolic blood pressure (< 90 mmHg) was not reached. To assess the potential blood pressure response associated with the act of titration, patients in the placebo and losartan 50 mg treatment groups with a sitting diastolic blood pressure of > or = 90 mmHg at week 6 were mock titrated (changed to a new tablet containing the same study medication and dose). Sitting diastolic blood pressure was also evaluated at the end of the trial during a 1-week off-drug period to assess for rebound hypertension. At week 6, patients in the active-drug-treatment arms experienced significantly greater peak (6 h post-dose) and trough (24 h post-dose) reduction in systolic and diastolic sitting blood pressures compared with placebo (p < or = 0.01). Based on trough blood pressures at week 12, active drug (both arms) was more effective than placebo in lowering sitting diastolic blood pressure, with a very small additional benefit associated with increasing the dose of losartan to 100 mg in patients who did not reach the target blood pressure after the first 6 weeks on losartan 50 mg. There was no evidence of rebound hypertension during 1 week after withdrawal of losartan. The correlation between baseline plasma renin activity and reduction in peak and trough blood pressure at week 12, although statistically significant, was generally poor in the active treatment groups. In this trial, losartan was efficacious and well tolerated, and was similar to placebo with regard to adverse-experience profile. Adverse experiences that could reasonably be related to excessive lowering of blood pressure were not common and there was no evidence of rebound hypertension.


Asunto(s)
Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Antihipertensivos/efectos adversos , Compuestos de Bifenilo/efectos adversos , Presión Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Imidazoles/efectos adversos , Losartán , Masculino , Persona de Mediana Edad , Placebos , Postura , Renina/sangre , Sístole/efectos de los fármacos , Tetrazoles/efectos adversos
4.
Cardiovasc Drugs Ther ; 10(3): 313-9, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8877074

RESUMEN

The antihypertensive activity and safety of losartan, a specific and selective antagonist of angiotensin II (subtype 1) receptors, was evaluated in 100 inpatients with mild to moderate essential hypertension. After a 2-week, single-blind, out patient placebo lead-in period, the last 2 days of which included inpatient monitoring of baseline blood pressure, the patients were assigned randomly to receive once-daily doses of either placebo; 50, 100, or 150 mg losartan; or 10 mg enalapril. Patients were treated double blind for 5 days, followed by a day for the study of drug withdrawal. Beginning with the first dose, the three doses of losartan and enalapril significantly decreased peak and trough systolic and diastolic blood pressures compared with placebo (p < or = 0.05). The area under the blood pressure curve was analyzed as an assessment of total blood pressure change throughout the day. On day 1, total blood pressure reduction with losartan (50-150 mg) was slightly less than with enalapril. By day 5 of double-blind treatment, the reduction in blood pressure in these groups was similar, suggesting that losartan has a slower onset of action than enalapril. No rebound hypertension was observed after study-drug discontinuation. Losartan was well tolerated in this trial, with an adverse event profile similar to placebo and enalapril.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Enalapril/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adulto , Anciano , Antagonistas de Receptores de Angiotensina , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Antihipertensivos/administración & dosificación , Antihipertensivos/farmacología , Compuestos de Bifenilo/administración & dosificación , Compuestos de Bifenilo/farmacología , Monitoreo Ambulatorio de la Presión Arterial , Método Doble Ciego , Enalapril/administración & dosificación , Enalapril/farmacología , Femenino , Humanos , Imidazoles/administración & dosificación , Imidazoles/farmacología , Pacientes Internos , Losartán , Masculino , Persona de Mediana Edad , Placebos , Método Simple Ciego , Tetrazoles/administración & dosificación , Tetrazoles/farmacología
5.
Arch Intern Med ; 156(3): 278-85, 1996 Feb 12.
Artículo en Inglés | MEDLINE | ID: mdl-8572837

RESUMEN

BACKGROUND: Angiotensin II acts at the cellular level through specific angiotensin II subtype I, AT-1 receptors. Losartan is the first of a new class of antihypertensive agents that specifically block angiotensin II at AT-1 receptors. By acting on complementary and different pharmacologic mechanisms, the concomitant use of low doses of hydrochlorothiazide with losartan may offer an additive antihypertensive activity with fewer adverse experiences. METHODS: This double-blind study evaluated losartan concomitantly administered with hydrochlorothiazide as initial therapy in 703 patients with essential hypertension. RESULTS: The greatest reduction in blood pressure was observed in the 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide group (17.2 mm Hg in sitting systolic blood pressure and 13.2 mm Hg in sitting diastolic blood pressure [P < or = .001]), and the effects of the two components appeared to be additive. Seventy-eight percent of the patients treated with 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide had an excellent or good antihypertensive response (sitting diastolic blood pressure < 90 mm Hg or > or = 90 mm Hg with a reduction of 10 mm Hg or more). Peak (6 hours after dosing) and trough placebo-adjusted ratios for the losartan-hydrochlorothiazide groups ranged from 62% to 85%, indicating that there was a smooth reduction in sitting diastolic blood pressure that was sustained over 24 hours. The most common clinical adverse experiences (> or = 4%) that occurred with an incidence slightly greater than that reported by the placebo-treated patients were headache, asthenia or fatigue, dizziness, sinusitis, and upper respiratory infection. CONCLUSION: The concomitant administration of losartan potassium, 50 mg, with 12.5 mg of hydrochlorothiazide once daily produced an additive reduction in trough sitting systolic and diastolic blood pressure and was well tolerated.


Asunto(s)
Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adulto , Anciano , Antihipertensivos/administración & dosificación , Compuestos de Bifenilo/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Método Doble Ciego , Esquema de Medicación , Sinergismo Farmacológico , Quimioterapia Combinada , Femenino , Humanos , Hidroclorotiazida/administración & dosificación , Hipertensión/fisiopatología , Imidazoles/administración & dosificación , Losartán , Masculino , Persona de Mediana Edad , Tetrazoles/administración & dosificación , Resultado del Tratamiento
6.
J Hypertens ; 14(2): 263-70, 1996 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8728306

RESUMEN

OBJECTIVE: To compare the efficacy and safety of a regimen of losartan potassium (losartan) and a regimen of enalapril maleate (enalapril) in a randomized trial of patients with severe hypertension in which the initial treatments were blinded. DESIGN AND METHODS: Seventy-five patients, 23-74 years of age, with sitting diastolic blood pressure of 115-130mmHg, were enrolled in a 12-site multicenter study. The primary efficacy parameters were the change in trough systolic and diastolic blood pressure, as well as response to treatment in terms of categories of hypertensive response. RESULTS: A gradual reduction in mean sitting diastolic blood pressure was observed in all patients treated from week 1 to 12 (10-29mmHg for the losartan regimen and 14-32 mmHg for the enalapril regimen). At week 4, a substantial number of patients remained on monotherapy at either the initial dose or double the dose of losartan (52%) or enalapril (72%). The blood pressure curves for each treatment were parallel over time. The enalapril-based regimen elicited a statistically significantly greater reduction in blood pressure than the losartan-based regimen, although the mean differences in the blood pressure response between the two treatment groups was small. Based on sitting diastolic blood pressure < 90 mmHg or a reduction in blood pressure of at least 10 mmHg, 98% of the patients assigned to the losartan regimen and 100% of the patients assigned to the enalapril regimen had a satisfactory response with a regimen of one to three antihypertensive drugs. Headache was the most common adverse experience in both treatment groups (occurring in 22% of patients assigned to the losartan regimen and 20% of patients assigned to the enalapril regimen). CONCLUSIONS: In this study, the losartan-based regimen effectively lowered blood pressure, was generally well tolerated, and was generally similar to the enalapril-based regimen in the treatment of patients with severe hypertension.


Asunto(s)
Antagonistas de Receptores de Angiotensina , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Enalapril/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Método Doble Ciego , Quimioterapia Combinada , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipertensión/fisiopatología , Losartán , Masculino , Persona de Mediana Edad
7.
Blood Press ; 5(1): 32-40, 1996 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8777471

RESUMEN

The purpose of this trial was to evaluate the antihypertensive efficacy of the concomitant administration of selected doses of hydrochlorothiazide (HCTZ) on a background of losartan potassium (losartan) 50 mg, a selective angiotensin II receptor antagonist. Patients with essential hypertension ( > or = 95 mmHg inclusion criteria) with a mean sitting diastolic blood pressure (SiDBP) of 105 +/- 0.4 (S.E.) mmHg entered a 4-week, single-blind monotherapy period of losartan 50 mg once daily. At the end of the monotherapy period, patients whose blood pressure was adequately controlled were discontinued. Patients whose blood pressure was partially controlled based on a SiDBP > 92 mmHg entered a 12 week double-blind period and were randomly assigned to either receive placebo (n = 80), HCTZ 6.25 mg (n = 80), HCTZ 12.5 mg (n = 72) or HCTZ 25 mg (n = 80) in addition to losartan 50 mg. During the losartan monotherapy period, there was a 4 mmHg fall in SiDBP with a further fall of 5 mmHg after 12 weeks of double-blind therapy in the losartan/placebo control group. Based on the between group differences in BP change from the end of the losartan monotherapy period (baseline) to end of 12 weeks of double-blind, the concomitant administration of a very low dose of HCTZ (6.25 mg) with losartan did not significantly decrease SiDBP compared with the fall in blood pressure in the losartan/placebo control group (diff. between groups = -2 (95% C.I.[-4.1, +0.9] mmHg)). However, the concomitant administration of HCTZ 12.5 or 25 mg with losartan 50 mg resulted in significantly different (p < or = 0.05) reductions in diastolic blood pressure compared to the losartan/placebo group (diff. between groups = -4 (95% C.I. [-6.3, -1.1] mmHg) for 12.5mg combination group; -6 (95% C.I. [-8.3, -3.3]) mmHg for the HCTZ 25 mg combination group). The proportions of patients treated with losartan plus HCTZ 12.5 mg or 25 mg that achieved a trough SiDBP < 88 mmHg or a trough SiDBP > or = 88 mmHg but with a decrease of at least 5 mmHg were 71% and 83%, respectively. The percentage of clinical adverse experiences that were considered drug-related as assessed by the investigator were generally similar across all treatment groups. There were no reports of orthostatic hypotension in any of the treatment groups. Changes in serum glucose, potassium and uric acid were not appreciably different amongst the treatment groups. In summary, in patients with predominantly moderate to severe essential hypertension, the addition of HCTZ 12.5 mg or 25 mg to losartan 50 mg produced effective control of blood pressure in a substantial majority of patients who only partially responded to losartan monotherapy. There were no differences amongst the treatment groups with respect to drug-related adverse experiences in this trial.


Asunto(s)
Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adulto , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Astenia/inducido químicamente , Compuestos de Bifenilo/administración & dosificación , Compuestos de Bifenilo/efectos adversos , Presión Sanguínea/efectos de los fármacos , Ensayos Clínicos Controlados como Asunto , Tos/inducido químicamente , Mareo/inducido químicamente , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Quimioterapia Combinada , Femenino , Cefalea/inducido químicamente , Humanos , Hidroclorotiazida/administración & dosificación , Hidroclorotiazida/efectos adversos , Imidazoles/administración & dosificación , Imidazoles/efectos adversos , Losartán , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/inducido químicamente , Tetrazoles/administración & dosificación , Tetrazoles/efectos adversos , Factores de Tiempo
8.
J Hum Hypertens ; 9(11): 861-7, 1995 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-8583463

RESUMEN

This 12-week, open-label study was conducted to gain experience with losartan potassium, an angiotensin II receptor antagonist, in patients with severe hypertension. Patients were either untreated or withdrawn from current therapy for at least 48 h before initiation of losartan 50 mg once daily. Patients were titrated to 100 mg as needed to achieve a goal of sitting diastolic blood pressure (SiDBP) 90 or 95 mm Hg. Hydrochlorothiazide (12.5 mg once daily titrated to 25 mg) was added and followed by either a dihydropyridine calcium channel blocker (CCB) and/or atenolol, if BP was not controlled. A total of 179 patients with a pretreatment mean baseline BP of 172 +/- 17/112 +/- 18 mm Hg enrolled in the trial and BP was recorded 24 h after dosing at baseline and weeks 2, 4, 8 and the final week (10-12 weeks). The mean reductions in SiDBP from baseline were 7.3, 9.3, 15.9 and 18.9 mm Hg, respectively, and these changes from baseline were statistically significant, P < 0.001. At the end of the trial, 22% of patients remained on losartan monotherapy, 30% required the addition of hydrochlorothiazide (HCTZ) and 31% required both HCTZ and a CCB; 11% required HCTZ and atenolol while 4% required HCTZ, a CCB and atenolol; 2% of patients were on regimens not specified by the protocol. SiDBP < 90 mm Hg was achieved in 68 patients by the final visit; 24% of these patients were treated with losartan monotherapy (50 or 100 mg), 41% achieved control with the addition of HCTZ (12.5 or 25 mg) and 24% required triple therapy which included losartan, HCTZ and a CCB. As assessed by the investigator, 25% of the patients in the study had drug-related clinical adverse experiences. Headache was the most frequently reported clinical adverse event (26% of patients). No clinically significant changes in laboratory parameters were observed. It is concluded that losartan potassium can be used as initial therapy for patients with severe hypertension and can be administered concurrently with hydrochlorothiazide, calcium channel blockers and atenolol.


Asunto(s)
Antagonistas de Receptores de Angiotensina , Compuestos de Bifenilo/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adolescente , Adulto , Anciano , Antihipertensivos/administración & dosificación , Antihipertensivos/uso terapéutico , Atenolol/administración & dosificación , Atenolol/uso terapéutico , Compuestos de Bifenilo/administración & dosificación , Compuestos de Bifenilo/efectos adversos , Dihidropiridinas/administración & dosificación , Dihidropiridinas/uso terapéutico , Quimioterapia Combinada , Femenino , Humanos , Hidroclorotiazida/administración & dosificación , Hidroclorotiazida/uso terapéutico , Hipertensión/fisiopatología , Imidazoles/administración & dosificación , Imidazoles/efectos adversos , Losartán , Masculino , Persona de Mediana Edad , Sistema Renina-Angiotensina/efectos de los fármacos , Tetrazoles/administración & dosificación , Tetrazoles/efectos adversos , Resultado del Tratamiento
9.
J Hum Hypertens ; 9(9): 765-71, 1995 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8551492

RESUMEN

This study investigated the anti-hypertensive efficacy and tolerability of once-daily losartan potassium (50 mg titrated to 100 mg), an angiotensin II receptor antagonist, compared with once daily felodipine extended release (ER) (5 mg titrated to 10 mg), a calcium channel blocker, after 12 weeks of therapy in elderly hypertensive patients. Following a 4-week, single-blind, placebo baseline period, qualifying patients were randomly allocated to 12 weeks of double-blind treatment with losartan potassium or felodipine ER. After 6 weeks, patients with a 24 h post-dose sitting diastolic blood pressure > or = 90 mm Hg had their dose doubled for the remaining 6 weeks. At 6 weeks, there was a greater BP response for felodipine ER than losartan potassium in elderly patients with mild to moderate hypertension. However, after 12 weeks of therapy, losartan potassium reduced BP as effectively as felodipine ER with no differences in mean BP reduction or anti-hypertensive response category between treatment groups. In this study, both treatments were well tolerated; felodipine ER was associated with a numerically higher incidence of headache and oedema while the incidence of asthenia was numerically higher in losartan-treated patients.


Asunto(s)
Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Bloqueadores de los Canales de Calcio/uso terapéutico , Felodipino/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Anciano , Anciano de 80 o más Años , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Compuestos de Bifenilo/administración & dosificación , Compuestos de Bifenilo/efectos adversos , Bloqueadores de los Canales de Calcio/administración & dosificación , Bloqueadores de los Canales de Calcio/efectos adversos , Preparaciones de Acción Retardada , Método Doble Ciego , Felodipino/administración & dosificación , Felodipino/efectos adversos , Femenino , Humanos , Hipertensión/fisiopatología , Imidazoles/administración & dosificación , Imidazoles/efectos adversos , Losartán , Masculino , Tetrazoles/administración & dosificación , Tetrazoles/efectos adversos , Resultado del Tratamiento
10.
Hypertension ; 26(1): 112-7, 1995 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7607713

RESUMEN

The purpose of this multicenter trial was to compare the antihypertensive efficacy and safety of losartan potassium (losartan), a selective angiotensin II receptor antagonist, when added to hydrochlorothiazide in hypertensive patients whose blood pressure was not adequately controlled by 25 mg hydrochlorothiazide monotherapy. After a 4-week monotherapy period of 25 mg hydrochlorothiazide, 304 patients with trough (22 to 26 hours postdose) sitting diastolic pressure between 93 and 120 mm Hg were maintained on 25 mg hydrochlorothiazide and randomized double-blind into treatment arms consisting of either 25, 50, or 100 mg losartan or placebo once daily for 12 weeks. The reductions in sitting diastolic pressure for patients treated with 25, 50, or 100 mg losartan concomitantly administered with 25 mg hydrochlorothiazide were significantly greater (P < or = .05) than the reductions observed in the 25 mg hydrochlorothiazide plus placebo group beginning 1 week after randomization. The antihypertensive response in all groups was greater at week 3 than week 1, with some additional decrease in blood pressure in some groups at later times. Sitting systolic pressures were also significantly reduced in each group over time. Standing blood pressures at week 12 were similar to sitting blood pressures. A dose-response relationship to losartan was observed in this patient population. The percentages of the total drug-related clinical adverse experiences as assessed by the investigator were generally similar in the 25, 50, and 100 mg losartan plus 25 mg hydrochlorothiazide groups (10.3%, 24.4%, and 20.0%, respectively) compared with the placebo plus 25 mg hydrochlorothiazide group (24.7%).(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Angiotensina II/antagonistas & inhibidores , Antagonistas de Receptores de Angiotensina , Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/administración & dosificación , Hidroclorotiazida/administración & dosificación , Hipertensión/tratamiento farmacológico , Imidazoles/administración & dosificación , Tetrazoles/administración & dosificación , Antihipertensivos/farmacología , Compuestos de Bifenilo/farmacología , Diástole/efectos de los fármacos , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Hidroclorotiazida/farmacología , Imidazoles/farmacología , Losartán , Masculino , Persona de Mediana Edad , Postura , Potasio/sangre , Sístole/efectos de los fármacos , Tetrazoles/farmacología , Factores de Tiempo , Ácido Úrico/sangre
11.
J Hypertens Suppl ; 13(1): S35-41, 1995 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18800454

RESUMEN

INTRODUCTION: Losartan potassium, an orally active, highly selective AT1 angiotensin II receptor inhibitor, effectively reduces blood pressure by direct receptor blockade, thereby lessening the likelihood of angiotensin converting enzyme (ACE) inhibitor-associated side effects such as dry cough or possibly angioedema. STUDY DESIGN: In this multinational, double-blind, randomized, parallel study, the efficacy and tolerability of once-daily losartan (50 mg) versus once-daily ACE inhibitor (captopril; 50 mg) was evaluated in 163 patients with mild to moderate hypertension. Non-responders after a 6-week treatment period had the dosage doubled for both study drugs until the end of study (week 12). RESULTS: Mean reductions in trough sitting diastolic blood pressure were significantly greater in the losartan group at week 6 (7.8 mmHg) and week 12 (9.1 mmHg) than in the captopril group (5.2 and 5.7 mmHg, respectively). Losartan and captopril were well tolerated. Headache was the most common adverse event reported in both groups. CONCLUSIONS: It was concluded that a once-daily administration of losartan was significantly more effective in this study in lowering sitting diastolic blood pressure than once-daily administration of captopril in patients with mild to moderate essential hypertension. Both losartan and captopril regimes were well tolerated.


Asunto(s)
Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Captopril/uso terapéutico , Hipertensión/tratamiento farmacológico , Losartán/uso terapéutico , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Bloqueadores del Receptor Tipo 1 de Angiotensina II/farmacología , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Presión Sanguínea/efectos de los fármacos , Captopril/efectos adversos , Captopril/farmacología , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Cefalea/inducido químicamente , Humanos , Hipertensión/fisiopatología , Losartán/efectos adversos , Losartán/farmacología , Masculino , Persona de Mediana Edad
12.
J Hypertens Suppl ; 13(1): S77-80, 1995 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18800461

RESUMEN

AIM: To examine the safety profile and tolerability of losartan potassium (losartan), a selective antagonist of the angiotensin II type 1 (AT1) receptor. PATIENTS AND METHODS: Approximately 2000 hypertensive patients were treated in double-blind clinical trials with losartan, placebo or other antihypertensive drug classes. RESULTS: Headache (14.1%), upper respiratory infection (6.5%), dizziness (4.1%), asthenia/fatigue (3.8%) and coughing (3.1%) were the most commonly reported clinical adverse experiences in patients treated with losartan. These adverse experiences were also commonly reported in patients treated with a placebo: 17.2, 5.6, 2.4, 3.9 and 2.6%, respectively. A dry cough was reported by 8.8% of patients treated with angiotensin converting enzyme (ACE) inhibitors, statistically greater than that reported in patients treated with losartan and placebo, 3.1 and 2.6%, respectively (P < 0.001, losartan versus ACE inhibitors). Only dizziness was more often considered drug-related in losartan-treated patients (2.4%) than in patients who received placebo (1.3%). In controlled clinical trials, losartan was better tolerated than other antihypertensive agents as determined by the incidence of patients reporting any drug-related adverse experiences. The rate of withdrawal due to clinical adverse experiences in patients treated with losartan was 2.3% compared to 3.7% in patients treated with a placebo. No adverse laboratory results were unexpected or of clinical importance. First-dose hypotension occurred rarely with losartan, and withdrawal effects such as rebound hypertension were not observed in clinical trials. There were no clinically important differences in the clinical or laboratory safety profiles for the demographic subgroups of age, sex or race. CONCLUSION: In controlled clinical trials losartan has demonstrated an excellent tolerability profile.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Atenolol/efectos adversos , Felodipino/efectos adversos , Hipertensión/tratamiento farmacológico , Losartán/efectos adversos , Antagonistas Adrenérgicos beta/efectos adversos , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Atenolol/uso terapéutico , Bloqueadores de los Canales de Calcio/efectos adversos , Bloqueadores de los Canales de Calcio/uso terapéutico , Ensayos Clínicos Controlados como Asunto , Tos/inducido químicamente , Mareo/inducido químicamente , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Fatiga/inducido químicamente , Felodipino/uso terapéutico , Femenino , Cefalea/inducido químicamente , Humanos , Incidencia , Losartán/uso terapéutico , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/inducido químicamente
13.
Am J Hypertens ; 8(6): 578-83, 1995 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-7662242

RESUMEN

The objective of this study was to compare the antihypertensive efficacy and tolerability of losartan potassium (losartan) and atenolol in patients with mild-to-moderate essential hypertension. This was a multinational, prospective, randomized, 12-week double-blind parallel study with a follow-up of 4 to 10 days posttreatment to assess any adverse effects of abrupt therapy withdrawal. Two hundred two patients were randomized (2:1) to treatment with losartan or atenolol, 50 mg once daily. Patients were titrated after 6 weeks to 100 mg once daily if their blood pressure was uncontrolled (sitting diastolic blood pressure > or = 90 mm Hg). Trough sitting diastolic blood pressure reductions at weeks 6 and 12 were similar in both the losartan (-9.2 mm Hg and -8.3 mm Hg) and atenolol (-10.8 mm Hg and -10.1 mm Hg) groups and a similar percentage of patients responded to each drug. Both agents were generally well tolerated, although eight patients (two patients taking losartan, and six taking atenolol) were withdrawn because of clinical adverse events (P < or = .05). Reduction in pulse rate from baseline averaged 10 beats/min in the atenolol group with no pulse rate reduction observed in the losartan group (P < .01). No evidence of rebound hypertension was observed in either group. In conclusion, losartan was as efficacious as atenolol in blood pressure reduction, and was at least as well tolerated.


Asunto(s)
Antihipertensivos/uso terapéutico , Atenolol/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adulto , Anciano , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Atenolol/administración & dosificación , Atenolol/efectos adversos , Compuestos de Bifenilo/administración & dosificación , Compuestos de Bifenilo/efectos adversos , Método Doble Ciego , Femenino , Humanos , Hipertensión/fisiopatología , Imidazoles/administración & dosificación , Imidazoles/efectos adversos , Losartán , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Pulso Arterial/efectos de los fármacos , Tetrazoles/administración & dosificación , Tetrazoles/efectos adversos , Factores de Tiempo
14.
Hypertension ; 25(6): 1345-50, 1995 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-7768585

RESUMEN

The efficacy and safety of various doses of losartan potassium, a specific and selective angiotensin II receptor antagonist, were compared with those of placebo and enalapril maleate 20 mg in patients with mild to moderate essential hypertension in a randomized, double-blind, parallel study. We randomly allocated 576 patients at the end of a 4-week placebo baseline period to 8 weeks of once-daily double-blind treatment with losartan potassium 10, 25, 50, 100, or 150 mg, enalapril maleate 20 mg, or placebo. After 8 weeks of treatment, mean reductions from baseline in supine systolic/diastolic pressure 24 hours after dosing (trough) for losartan potassium 10, 25, 50, 100, and 150 mg, enalapril maleate 20 mg, and placebo were 7.6/7.9, 7.8/6.8, 13.0/10.1, 8.9/9.9, 10.5/9.7, 14.7/11.2, and 3.8/5.6 mm Hg, respectively. Compared with mean changes in supine diastolic pressure in the placebo group, losartan potassium 50 to 150 mg and enalapril maleate 20 mg produced clinically important and statistically significant reductions (P < or = .01) in blood pressure. At 24 hours after dosing, the blood pressure changes obtained with losartan potassium 50 mg were essentially identical to those obtained with enalapril maleate 20 mg. While there was a dose-related effect with losartan potassium from 10 to 50 mg at peak (6 hours after dosing), doses of 10 and 25 mg were not consistently different from placebo 24 hours after dosing. To assess the once-daily effect of losartan potassium, trough-to-peak ratios of the mean changes in supine diastolic pressure after 8 weeks of treatment were calculated.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Angiotensina II/antagonistas & inhibidores , Compuestos de Bifenilo/uso terapéutico , Enalapril/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Compuestos de Bifenilo/efectos adversos , Presión Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Enalapril/efectos adversos , Femenino , Humanos , Imidazoles/efectos adversos , Losartán , Masculino , Persona de Mediana Edad , Tetrazoles/efectos adversos
15.
J Cardiovasc Pharmacol ; 25(4): 511-7, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7596116

RESUMEN

We examined the haemodynamic and renal response to oral losartan potassium (100 mg) during activation of the renin system in humans. Eight healthy volunteers followed a low-salt (40 mmol sodium) diet for 4 days on four occasions 2 weeks apart. Double-blind salt depletion was achieved by 3-day administration of frusemide (40 mg twice daily, b.i.d.) with placebo salt replacement, salt repletion by placebo frusemide (b.i.d.), and active salt replacement (100 mmol/day). On day 4, subjects received randomised double-blind placebo or losartan. Prestudy salt depletion was associated with nonsignificant decreases in serum sodium (138 +/- 2 mM), potassium (3.5 +/- 0.2 mM) and increased urea (6.5 +/- 1.1 mM), and creatinine (91 +/- 6 microM) as compared with screening. Prestudy (day 3) 24-h urinary volume was similar during deplete preparation (placebo 1.707 +/- 0.81 L, losartan 1.509 +/- 0.626 L) or deplete preparation (placebo 1.726 +/- 0.5 L, losartan 1.764 +/- 0.52 L), but sodium excretion was greater during replete preparation. Salt replete supine blood pressure (BP) profiles showed little effect of losartan (mean maximal supine BP -9 +/- 6 mm Hg) as compared with placebo (-1 +/- 4 mm Hg), with a similar relative result for erect BP. After salt depletion, losartan caused a greater response in both supine (-24 +/- 9) and erect (-33 +/- 15) BP than did placebo (supine -12 +/- 5, erect -14 +/- 9). In this protocol after salt depletion, losartan caused a transient increase in urea and creatinine (143 +/- 40 microML) 8 h after dosing as compared with placebo (105 +/- 13 microM).(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Antihipertensivos/farmacología , Compuestos de Bifenilo/farmacología , Hemodinámica/efectos de los fármacos , Imidazoles/farmacología , Riñón/efectos de los fármacos , Sodio/deficiencia , Sodio/farmacología , Tetrazoles/farmacología , Adulto , Aldosterona/orina , Presión Sanguínea/efectos de los fármacos , Creatinina/sangre , Método Doble Ciego , Electrólitos/metabolismo , Furosemida/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Losartán , Masculino , Renina/sangre
16.
Am J Cardiol ; 75(12): 793-5, 1995 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-7717281

RESUMEN

This report presents data on the safety and tolerability of losartan potassium (losartan), a selective antagonist of the angiotensin II AT-1 receptor, in approximately 2,900 hypertensive patients treated in double-blind clinical trials. In these studies, headache (14.1%), upper respiratory infection (6.5%), dizziness (14.1%), asthenia/fatigue (3.8%), and cough (3.1%) were the clinical adverse experiences most often reported in patients treated with losartan. These adverse experiences were also frequently reported in patients receiving placebo: 17.2%, 5.6%, 2.4%, 3.9%, and 2.6%, respectively. Dry cough as an adverse event was reported in 8.8% of patients treated with angiotensin-converting enzyme inhibitors, and in 3.1% and 2.6% of patients treated with losartan or placebo, respectively. Only dizziness was considered "drug-related" more often in losartan-treated (2.4%) than placebo-treated (1.3%) patients. In controlled clinical trials, losartan was better tolerated than other antihypertensive agents as determined by the incidence of patients reporting any drug-related adverse experiences. Rates of discontinuation due to clinical adverse experiences in patients who received losartan monotherapy or losartan+hydrochlorothiazide were 2.3% and 2.8%, respectively, compared with placebo (3.7%). No laboratory adverse experiences were unexpected or of clinical importance. First-dose hypotension rarely occurred with losartan or with losartan plus hydrochlorothiazide, and withdrawal effects such as rebound hypertension were not observed in clinical trials. There were no clinically important differences in the clinical or laboratory safety profiles in the demographic subgroups for age, gender, or race. In controlled clinical trials, losartan demonstrated an excellent tolerability profile.


Asunto(s)
Angiotensina II/antagonistas & inhibidores , Antagonistas de Receptores de Angiotensina , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Atenolol/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Felodipino/uso terapéutico , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Antihipertensivos/administración & dosificación , Astenia/inducido químicamente , Atenolol/efectos adversos , Compuestos de Bifenilo/efectos adversos , Tos/inducido químicamente , Mareo/inducido químicamente , Método Doble Ciego , Fatiga/inducido químicamente , Felodipino/efectos adversos , Femenino , Cefalea/inducido químicamente , Humanos , Hidroclorotiazida/efectos adversos , Imidazoles/efectos adversos , Losartán , Masculino , Persona de Mediana Edad , Placebos , Infecciones del Sistema Respiratorio/inducido químicamente , Seguridad , Tetrazoles/efectos adversos
18.
Am J Hypertens ; 7(12): 1035-40, 1994 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-7702795

RESUMEN

Losartan potassium (DuP 753), an orally active angiotensin II receptor antagonist, is metabolized to a more potent active metabolite, E-3174, which contributes to losartan's long duration of action. The acute pharmacodynamic actions of intravenous (i.v.) E-3174 (20 mg infused over 4 h) were compared to placebo (vehicle) in two groups of patients with essential hypertension. Patients with supine diastolic blood pressure (SuDBP) of 100 to 120 mm Hg entered a 2-day inpatient phase and received vehicle on day 1. Patients with SuDBP > or = 95 mm Hg were randomized to double-blind treatment the next day. E-3174 significantly (P < .05) reduced SuDBP compared to placebo, beginning at approximately 100 min after the start of the infusion, with a maximum hypotensive effect at 8 h. Supine systolic blood pressure was also reduced by E-3174. Supine and standing heart rates did not differ between treatments. Mean E-3174 plasma levels were 324.6 ng/mL at 20 min and approximately 1000 ng/mL at the end of the 4-h infusion; during this time there was a modest decrease in blood pressure. Following the infusion, the relationship between plasma E-3174 levels and SuDBP was confounded by much larger decreases in blood pressure, which occurred as plasma drug concentrations declined. Urinary excretions of sodium, potassium, or chloride were not significantly altered by E-3174 nor was the fractional excretion of uric acid significantly different between groups. There were no drug-related or serious adverse experiences and no patient discontinued treatment due to an adverse experience.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Angiotensina II/antagonistas & inhibidores , Antihipertensivos/uso terapéutico , Hipertensión/tratamiento farmacológico , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Adulto , Anciano , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Presión Sanguínea/efectos de los fármacos , Método Doble Ciego , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipertensión/fisiopatología , Imidazoles/administración & dosificación , Imidazoles/efectos adversos , Inyecciones Intravenosas , Pruebas de Función Renal , Losartán , Masculino , Persona de Mediana Edad , Renina/sangre , Tetrazoles/administración & dosificación , Tetrazoles/efectos adversos , Ácido Úrico/sangre
19.
Eur Heart J ; 15 Suppl D: 139-44, 1994 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-7713103

RESUMEN

Losartan potassium (Cozaar) is an angiotensin II receptor antagonist (AT1 selective) which has undergone extensive clinical trials for the treatment of hypertension. This literature survey will review some of the pre-clinical findings with losartan in models of heart failure, and where appropriate, we will compare the haemodynamic findings in animals with similar studies completed in patients. The major conclusion from these trials is that losartan has clear haemodynamic benefits in patients in heart failure and that the drug appears to be well tolerated, with a low incidence of adverse experiences related to impaired renal function.


Asunto(s)
Angiotensina II/antagonistas & inhibidores , Antagonistas de Receptores de Angiotensina , Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Hemodinámica/efectos de los fármacos , Imidazoles/uso terapéutico , Tetrazoles/uso terapéutico , Angiotensina II/fisiología , Animales , Antihipertensivos/efectos adversos , Compuestos de Bifenilo/efectos adversos , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Insuficiencia Cardíaca/fisiopatología , Hemodinámica/fisiología , Humanos , Imidazoles/efectos adversos , Losartán , Ratas , Receptores de Angiotensina/fisiología , Ovinos , Tetrazoles/efectos adversos
20.
J Cardiovasc Pharmacol ; 21(5): 732-8, 1993 May.
Artículo en Inglés | MEDLINE | ID: mdl-7685442

RESUMEN

In a dose-ranging study, the angiotensin type I receptor antagonist losartan (DuP753/MK954) was administered orally to normal volunteers in whom the renin-angiotensin system (RAS) had been activated by a low sodium diet (40 mmol) and frusemide (40 mg twice daily) for 3 days before study. On the fourth day, subjects (n = 12) received placebo and three active doses (5, 10, 25, 50, or 100 mg) in a randomized, double-blind, three-panel, dose-ranging design. On the study day, 24-h urinary sodium excretion was approximately 10-20 mmol Na, with an increase in renin and aldosterone levels at baseline. Dose-dependent decreases in supine and erect blood pressures (BP) were statistically significant for 50 and 100 mg and were associated with a modest increase in supine heart rate (HR) at the higher dose. The peak BP decreases observed suggested that the highest dose studied (100 mg) was not necessarily the maximal response. Active treatments caused no increase in the sodium loss on the study day. Renin was significantly increased by doses > 10 mg in a dose-dependent fashion but there was little change in plasma aldosterone profile. Increase in renin was evident at doses (10 mg) below those significantly affecting overall BP (50 mg). Adverse symptoms were uncommon and limited to postural lightheadedness which was largely dose related. Our results indicate a BP and plasma renin dose-response relation for the orally active angiotensin II (AII) receptor blocker losartan in normotensive subjects with an activated RAS.


Asunto(s)
Angiotensina II/metabolismo , Antagonistas de Receptores de Angiotensina , Compuestos de Bifenilo/farmacología , Imidazoles/farmacología , Sodio/fisiología , Tetrazoles/farmacología , Adulto , Aldosterona/sangre , Presión Sanguínea/efectos de los fármacos , Dieta Hiposódica , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Electrólitos/orina , Furosemida/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Losartán , Masculino , Natriuresis/efectos de los fármacos , Renina/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...